Absolutely. This cash will go along way to extending the runway prior to the next capital raise. The longer this runway is pushed out the greater the chance of SP undergoing a re rating in light of positive clinical data results - which naturally means less dilution for current shareholders.I have my fingers crossed for a positive result in the UTI treatment study this FY. Whilst sepsis might be a bigger fish - I feel that UTI will be a quicker path to commercialisation.
GLTA
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.030(7.14%) |
Mkt cap ! $112.7M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 42.0¢ | 37.0¢ | $77.62K | 193.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30531 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 49884 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |